Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni has maintained a Buy rating on CervoMed (NASDAQ:CRVO) and increased the price target from $50 to $65.
April 08, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has reaffirmed its Buy rating on CervoMed and raised the price target from $50 to $65.
The upgrade in the price target by a reputable analyst firm like Canaccord Genuity typically signals a strong bullish sentiment towards the stock, suggesting an anticipated positive performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100